Hsc clinical trials controversy continues

Access through your institution Buy or subscribe _Olivieri replies_—The facts of this case are quite straightforward. The allegation that the Hospital for Sick Children (HSC) and the

University of Toronto "completely failed to support the efforts of Olivieri" is absolutely true, as is the implication that it did not support my right to publish findings about

L–1 (Deferiprone). Ultimately, the only support to me for legal protection came from the Canadian Medical Protective Associa–tion (CMPA), an organization that serves to protect physicians in

Canada from legal threats arising in the practice of medicine. The CMPA first limited its support to the issue of full disclosure of the perceived risk of Deferiprone to my Toronto patients

only. The CMPA declined to support disclosure of perceived risks to patients in international trials (of which I was the chair of the steering committee), to regulatory agencies (to which

applications were being made by Apotex for licensing, based in large part on earlier work by us) or to the scientific community. Two months after the abrupt termination of these trials by

Apotex, I was unable to fulfill these last three obligations without the risk of legal action by Apotex. The Hospital nevertheless stated, unequivocally, that it would not provide legal

counsel for me in this matter. Written records of this refusal are available. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your

institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access

to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read

our FAQs * Contact customer support REFERENCES * Tricta, F. _et al_. Long–term chelation therapy with the orally active iron chelator deferiprone in patients with thalassemia major.

Proceedings of the 6th International Conference on Thalassemia and the Haemoglobinopathies, April, 1997. * Tricta, F. _et al_. Randomized trial of deferiprone (L1) and deferoxamine (DFO) in

thalassemia major. Proceedings of the 6th International Conference on Thalassemia and the Haemoglobinopathies, April 1997. * Diav–Citrin, O., Atanackovic, G. & Koren, G. Correlation

between initial hepatic iron concentration and response to deferiprone (L1) in patients with beta–thalassemia major. _Clin. Pharm. Ther._ 192, PII– 77 (1998). Google Scholar  Download

references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Professor of Pediatrics and Medicine, University of Toronto, Canada Nancy Olivieri * Scientist, Medical Research Council of Canada,

Nancy Olivieri * Director, Haemoglobinopathy Programs, The Hospital for Sick Children and The Toronto Hospital, Nancy Olivieri Authors * Nancy Olivieri View author publications You can also

search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Olivieri, N. HSC clinical trials controversy continues.

_Nat Med_ 5, 3 (1999). https://doi.org/10.1038/4819 Download citation * Issue Date: January 1999 * DOI: https://doi.org/10.1038/4819 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative